The Claim
In individuals with nonalcoholic fatty liver disease, higher circulating levels of insulin-like growth factor binding protein 1 (IGFBP1) are associated with reduced hepatic lipid accumulation and lower markers of inflammation, as observed in human patients, mouse models, and liver cell cultures exposed to fatty acids.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with nonalcoholic fatty liver disease, higher levels of insulin-like growth factor binding protein 1 correlate with less fat buildup in the liver and lower levels of inflammatory markers.
See the scientific wording
In individuals with nonalcoholic fatty liver disease, higher circulating levels of insulin-like growth factor binding protein 1 (IGFBP1) are associated with reduced hepatic lipid accumulation and lower markers of inflammation, as observed in human patients, mouse models, and liver cell cultures exposed to fatty acids.
When IGFBP1 binds to a receptor called ITGB1 on liver cells, it turns off genes that make fat and turns on genes that burn fat. At the same time, it blocks signals that cause inflammation, reducing the production of inflammatory chemicals in the liver.
What the research says
1 studyScientists gave extra IGFBP1 protein to mice and liver cells with fatty liver, and it helped reduce fat and inflammation — which means higher levels of this protein likely help protect the liver, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.